Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Pharma Industry Analysis

UpdatedNov 07, 2025
DataAggregated Company Financials
Companies296
  • 7D3.9%
  • 3M21.2%
  • 1Y6.8%
  • YTD11.0%

In the last week, the Pharma industry is up 3.9%, with Eli Lilly up 11%. Meanwhile, Zoetis actually underperformed within the industry, shrinking 17% in the last week. In the last 12 months, the industry was up 6.8%. Earnings are forecast to grow by 12% annually.

Industry Valuation and Performance

Has the U.S. Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 07 Nov 2025US$2.0tUS$396.2bUS$70.8b17.9x27.6x4.9x
Sun, 05 Oct 2025US$1.9tUS$387.9bUS$60.9b20x31.7x5x
Tue, 02 Sep 2025US$1.8tUS$387.9bUS$61.0b20x29.1x4.6x
Thu, 31 Jul 2025US$1.8tUS$383.6bUS$59.8b17.3x29.3x4.6x
Sat, 28 Jun 2025US$1.7tUS$382.7bUS$61.2b18.6x28.3x4.5x
Mon, 26 May 2025US$1.6tUS$382.6bUS$61.2b16.9x26.9x4.3x
Wed, 23 Apr 2025US$1.7tUS$380.6bUS$48.4b16.1x35.5x4.5x
Fri, 21 Mar 2025US$1.9tUS$381.1bUS$41.3b16.9x45.6x4.9x
Sun, 16 Feb 2025US$1.8tUS$380.9bUS$39.0b18.1x46.9x4.8x
Tue, 14 Jan 2025US$1.8tUS$369.3bUS$31.2b17.9x57.7x4.9x
Thu, 12 Dec 2024US$1.8tUS$373.8bUS$30.6b19.2x60.1x4.9x
Sat, 09 Nov 2024US$1.9tUS$373.6bUS$30.3b21.7x61.7x5x
Mon, 07 Oct 2024US$2.0tUS$364.1bUS$25.2b18.5x78.5x5.4x
Wed, 04 Sep 2024US$2.1tUS$364.1bUS$25.5b17.9x81.5x5.7x
Fri, 02 Aug 2024US$1.9tUS$359.4bUS$22.2b16.1x85.6x5.3x
Sun, 30 Jun 2024US$1.9tUS$357.6bUS$13.8b16.1x140.9x5.4x
Tue, 28 May 2024US$1.9tUS$358.3bUS$14.1b16.1x133.3x5.2x
Thu, 25 Apr 2024US$1.8tUS$357.7bUS$29.8b20.4x60.9x5.1x
Sat, 23 Mar 2024US$1.9tUS$355.3bUS$22.6b19.8x82.6x5.3x
Mon, 19 Feb 2024US$1.9tUS$355.0bUS$23.9b28.3x79.6x5.4x
Wed, 17 Jan 2024US$1.8tUS$375.2bUS$33.9b27.6x52.6x4.7x
Fri, 15 Dec 2023US$1.7tUS$375.1bUS$33.9b27x49.6x4.5x
Sun, 12 Nov 2023US$1.6tUS$375.5bUS$34.1b26.5x47.6x4.3x
Tue, 10 Oct 2023US$1.7tUS$381.8bUS$43.8b18.5x38.4x4.4x
Thu, 07 Sep 2023US$1.7tUS$381.8bUS$43.9b19.2x38.8x4.5x
Sat, 05 Aug 2023US$1.7tUS$379.3bUS$43.5b21.5x38.7x4.4x
Mon, 03 Jul 2023US$1.8tUS$392.8bUS$60.2b18.7x29.2x4.5x
Wed, 31 May 2023US$1.7tUS$393.0bUS$60.6b17.8x27.4x4.2x
Fri, 28 Apr 2023US$1.7tUS$402.7bUS$63.2b17.1x26.1x4.1x
Sun, 26 Mar 2023US$1.6tUS$401.2bUS$69.4b14.7x22.4x3.9x
Tue, 21 Feb 2023US$1.6tUS$401.8bUS$68.4b18.8x23.9x4.1x
Thu, 19 Jan 2023US$1.7tUS$403.7bUS$70.6b17.6x23.9x4.2x
Sat, 17 Dec 2022US$1.7tUS$403.7bUS$70.7b16.7x24.6x4.3x
Mon, 14 Nov 2022US$1.7tUS$403.6bUS$71.1b12.9x23.6x4.2x
Price to Earnings Ratio

23.6x


Total Market Cap: US$1.7tTotal Earnings: US$71.1bTotal Revenue: US$403.6bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Pharma Industry Price to Earnings3Y Average 52.6x202320242025
Current Industry PE
  • Investors are pessimistic on the American Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 27.6x which is lower than its 3-year average PE of 52.6x.
  • The industry is trading close to its 3-year average PS ratio of 4.7x.
Past Earnings Growth
  • Both revenue and earnings for companies in the Pharmaceuticals industry have remained mostly flat over the last three years.
  • This means that sales and the cost of doing business have remained relatively consistent over this period and subsequently, so have profits.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market-1.75%
Healthcare1.03%
Pharma3.92%
Pharma3.92%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
LLY Eli LillyUS$937.4411.0%
+US$83.2b		17.6%PE45.6x
TEVA Teva Pharmaceutical IndustriesUS$24.4619.4%
+US$4.6b		43.0%PE39.4x
PFE PfizerUS$24.852.3%
+US$3.2b		-9.5%PE14.4x
RPRX Royalty PharmaUS$40.788.6%
+US$1.2b		55.6%PE22.8x
BMY Bristol-Myers SquibbUS$46.631.2%
+US$1.1b		-13.9%PE15.7x

Latest News

JNJ
US$186.97
Johnson & Johnson
7D
-1.1%
1Y
19.3%
RPRX
US$40.78
Royalty Pharma
7D
8.6%
1Y
55.6%
LLY
US$937.44
Eli Lilly
7D
11.0%
1Y
17.6%
XERS
US$7.71
Xeris Biopharma Holdings
7D
-20.6%
1Y
129.5%
TEVA
US$24.46
Teva Pharmaceutical Industries
7D
19.4%
1Y
43.0%
TERN
US$18.25
Terns Pharmaceuticals
7D
123.7%
1Y
158.5%
PRGO
US$14.93
Perrigo
7D
-28.0%
1Y
-43.4%
LGND
US$208.22
Ligand Pharmaceuticals
7D
8.8%
1Y
71.7%
BMY
US$46.63
Bristol-Myers Squibb
7D
1.2%
1Y
-13.9%
SUPN
US$47.27
Supernus Pharmaceuticals
7D
-14.3%
1Y
29.1%

SUPN: Upgrades And Revenue Outlook Will Shape Performance Amid Execution Risk

Analysts have raised their price target for Supernus Pharmaceuticals by over $4 to approximately $59.33 per share. This change is due to higher future revenue growth expectations and an improved outlook for key therapies.
ZTS
US$119.56
Zoetis
7D
-17.0%
1Y
-32.4%
PFE
US$24.85
Pfizer
7D
2.3%
1Y
-9.5%
ELVN
US$18.30
Enliven Therapeutics
7D
-23.7%
1Y
-36.9%
INDV
US$31.87
Indivior
7D
8.5%
1Y
210.9%
MRK
US$85.78
Merck
7D
-0.6%
1Y
-15.2%

Merck & Co., Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Nov 02
Merck & Co., Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
RGC
US$13.26
Regencell Bioscience Holdings
7D
-20.4%
1Y
7,181.5%